Krieman M J, Hershock D M, Greenberg I J, Vogel W H
Department of Pharmacology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107.
Neuropharmacology. 1992 Jan;31(1):33-8. doi: 10.1016/0028-3908(92)90157-k.
Adinazolam (ADI) is a new benzodiazepine with anxiolytic and antidepressant properties. To assess its effects on the acute stress response, rats were given a single intraperitoneal injection of 2.5 or 5.0 mg/kg of ADI and stressed for 1 hr by restraint. Neither dose of ADI had any effect on heart rate, blood pressure or norepinephrine (NE) and epinephrine (EP) in plasma in the resting rats. In the stressed animal, 2.5 and 5.0 mg/kg of ADI did not affect stress-induced increases in heart rate or blood pressure but both significantly reduced the stress-induced increases in plasma NE and EP. During certain stressful experiences in patients with abnormally-increased sympathetic drive, ADI may be therapeutically useful in reducing high levels of catecholamines.
阿地唑仑(ADI)是一种具有抗焦虑和抗抑郁特性的新型苯二氮䓬类药物。为评估其对急性应激反应的影响,给大鼠腹腔注射2.5或5.0毫克/千克的ADI,然后通过束缚使其应激1小时。两种剂量的ADI对静息大鼠的心率、血压或血浆中的去甲肾上腺素(NE)和肾上腺素(EP)均无影响。在应激动物中,2.5和5.0毫克/千克的ADI不影响应激诱导的心率或血压升高,但两者均显著降低了应激诱导的血浆NE和EP升高。在交感神经驱动力异常增加的患者经历某些应激情况时,ADI可能在降低高水平儿茶酚胺方面具有治疗作用。